- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07670923
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Inclusion Criteria
- Patients scheduled for elective non-intubated general anesthesia
- Age ranging from 65 to 80 years old
- American Society of Anesthesiologists (ASA) physical status class I-III
- Written informed consent signed by the patient or legal guardian
Exclusion Criteria
- Confirmed allergy to propofol, ciprofol or their excipients
- Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
- Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
- Severe hepatic or renal insufficiency
- Long-term regular use of sedatives or opioids
- Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%) Elimination Criteria
1. Patients with allergic reactions to study drugs or other severe complications during the trial
2. Severe hypoxemia requiring emergency endotracheal intubation
3. Severe hemodynamic instability occurring during induction
4. Incomplete monitoring data caused by equipment malfunction Randomization and Group Allocation A total of 108 eligible elderly patients undergoing elective non-intubated general anesthesia at the Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University will be recruited. A computer-generated random number sequence will allocate subjects at a 1:1 ratio into the ciprofol group (Group C) and the propofol group (Group P).
Observation Indicators
Baseline Demographic Data
Gender, age, height, weight, BMI, ASA classification, smoking history, alcohol consumption, underlying diseases, Modified Mallampati score, thyromental distance, snoring history, etc.
Primary Observation Indicators
Hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV, SVR) and respiratory parameters (SpO₂, respiratory rate (RR), PETCO₂) will be recorded at baseline, loss of consciousness, 30 s, 1 min, 2 min, 3 min, 4 min and 5 min after loss of consciousness.
Secondary Observation Indicators
- Baseline BIS value and minimum BIS value during induction
- Total induction dosage, induction time (from drug administration to MOAA/S ≤ 1), recovery time (from last drug administration to MOAA/S = 5)
- Incidence of adverse reactions: injection pain, involuntary movement, hiccup, hypotension, bradycardia, hypoventilation, apnea, hypoxemia, etc.
Anesthetic Protocol
All patients fast for 8 hours and abstain from clear liquids for 4 hours preoperatively. After entering the operating room, oxygen inhalation is initiated, upper limb venous access is established, and monitors including pulse oximetry, sidestream PETCO₂ monitor, continuous non-invasive arterial blood pressure monitor and bispectral index (BIS) monitor are connected.
Midazolam 0.01 mg/kg is administered intravenously first; stable circulatory and respiratory readings thereafter serve as baseline values. Ciprofol or propofol is then infused intravenously at 10 mL/min. Sedation depth is assessed every 5 seconds via MOAA/S scale; drug infusion is stopped once MOAA/S ≤ 1 (loss of consciousness). The total induction dose is recorded. All hemodynamic and respiratory indicators are documented at predefined time points.
Anesthesiologists may supplement 1/3 of the initial induction dose if the patient shows eye opening, verbal response or body movement, with an interval of at least 1 minute between supplemental doses.
Rescue Management Protocols
- Hypotension (SBP < 90 mmHg or MAP decreased by >20% from baseline lasting >2 min): ephedrine 6 mg IV
- Severe bradycardia (HR < 45 beats/min lasting >30 s): atropine 0.5 mg IV
- Hypoventilation (RR < 8 bpm, PETCO₂ less than half baseline or PETCO₂ ≥45 mmHg lasting >30 s)
- Apnea (no thoracic movement or flat PETCO₂ waveform lasting >10 s)
- Hypoxemia (SpO₂ < 93%) / severe hypoxemia (SpO₂ < 85%) For respiratory compromise, jaw thrust, increased oxygen flow or mask-assisted ventilation will be applied; emergency endotracheal intubation will be performed if necessary.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 4
Kontakty a umístění
Studijní kontakt
- Jméno: Hanxiang Ma Ma, master
- Telefonní číslo: 13519591508
- E-mail: mahanxiang@hotmail.com
Studijní záloha kontaktů
- Jméno: LI Mo Mo, Bachelor
- Telefonní číslo: 17752025907
- E-mail: ml185030153@163.com
Studijní místa
-
-
Ningxia
-
Yinchuan, Ningxia, Čína, 750000
- Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Patients scheduled for elective non-intubated general anesthesia
- Age ranging from 65 to 80 years old
- American Society of Anesthesiologists (ASA) physical status class I-III
- Written informed consent signed by the patient or legal guardian
Exclusion Criteria:
- Confirmed allergy to propofol, ciprofol or their excipients
- Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
- Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
- Severe hepatic or renal insufficiency
- Long-term regular use of sedatives or opioids
- Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%)
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Ciprofol treatment group
This group plans to enroll a total of 54 elderly patients aged 65-80 who will undergo brief procedures without intubation, using spontaneous respiration under general anesthesia.
The intravenous infusion of cyclopropane hydrochloride injection will be administered at a constant rate of 10 ml/min.
The administration will cease when the MOAA/S score is ≤1.
Throughout the procedure, hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV,SVR), and respiratory parameters (SpO₂, respiratory rate (RR), PETCO₂), and various anesthetic adverse reactions will be monitored within the first 5 minutes after induction.
The safety of the medication will be evaluated in comparison with the control group
|
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point.
This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
|
|
Aktivní komparátor: Propofol Control group
This study aims to enroll 54 elderly patients aged 65-80 with short procedures and no need for intubation, who will receive propofol intravenously at a constant rate of 10 ml/min until their MOAA/S score drops to ≤1 point.
Circulatory and respiratory parameters, as well as adverse events, will be recorded simultaneously 5 minutes after induction.
This will allow for a parallel comparison of the two medications' effects on the circulatory and respiratory systems of elderly patients with the propofol control group.
|
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point.
This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Comparison of hemodynamic and respiratory function changes within 5 minutes of anesthesia induction
Časové okno: 5 minutes after induction of anesthesia
|
The primary objective of this study was to evaluate the degree of circulatory and respiratory suppression induced by two types of anesthesia drugs in elderly patients.
Continuous, non-invasive monitoring was conducted on the baseline conditions before administration for patients aged 65 to 80 undergoing short procedures without intubation and with spontaneous respiration under general anesthesia.
Additionally, measurements were taken at 1 minute, 2 minutes, 3 minutes, 4 minutes, and 5 minutes after induction to assess circulatory and respiratory functions.
Statistical analysis was performed to compare the changes in HR, SBP, DBP, MAP, CO, SV, SVR, PETCO2, RR, and SPO2 within the 5-minute induction period.
A comprehensive assessment of the dual safety of circulatory and respiratory systems was conducted
|
5 minutes after induction of anesthesia
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Brain electrical activity sedation depth (BIS)
Časové okno: 5 minutes after induction of anesthesia
|
lowest BIS value throughout the induction process, BIS value immediately upon loss of consciousness.
|
5 minutes after induction of anesthesia
|
|
incidence of induction period circulatory/respiratory adverse events
Časové okno: 5 minutes after induction of anesthesia
|
Proportion of adverse events, including low blood pressure, bradycardia, inadequate ventilation, apnea, and hypoxemia, occurring within 5 minutes of induction
|
5 minutes after induction of anesthesia
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- Li Mo-2026-06-22
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Ciprofol Injection
-
Beijing Boren HospitalUkončenoPokročilý pevný nádor | Recidivující/refrakterní lymfomČína
-
Northern Jiangsu People's HospitalAktivní, ne náborKvalita pooperační rekonvalescenceČína
-
Zhejiang Cancer HospitalNábor
-
Jiangsu Renocell Biotech CompanyZatím nenabírámeSystémová skleróza
-
Beijing Tiantan HospitalNeurodawn Pharmaceutical Co., Ltd.DokončenoAkutní ischemická mrtviceČína
-
Peking University Shenzhen HospitalNábor
-
Bio-Thera SolutionsDokončeno
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Dokončeno
-
Capital Medical UniversityNáborMechanická ventilace | Sedace a analgezieČína